Rajavelu Esther's Form 4 filing
Spero Therapeutics, Inc.SPRO · filed Nov 10, 2026
- Accession no.
- 0001193125-26-455873
- Filed
- Nov 10, 2026, 6:29 PM ET
- Trade date
- Nov 9, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $42.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rajavelu EstherCIK 0001903716 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Common Stock | SSaleDisposed | −40,851 | $1.04 | −$42,485.04 | 946,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Chief Executive Officer and Chief Financial Officer